Prostaglandin D2 expression is prognostic in high-grade serous ovarian cancer

Imagem de Miniatura
Arquivos
art_ALVES_Prostaglandin_D2_expression_is_prognostic_in_highgrade_serous_2019.PDF (601.04 KB)
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPANDIDOS PUBL LTD
Autores
ALVES, Mariana Rezende
AMARAL, Nayra Soares Do
MARCHI, Fabio Albuquerque
SILVA, Felipe Ilelis De Barros
COSTA, Alexandre Andre Balieiro Anastacio Da
BAIOCCHI, Glauco
SOARES, Fernando Augusto
BROT, Louise De
ROCHA, Rafael Malagoli
Citação
ONCOLOGY REPORTS, v.41, n.4, p.2254-2264, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
To identify biomarkers that could predict response or lack of response to conventional chemotherapy at the time of diagnosis of high-grade serous ovarian carcinoma (HGSOC), the present study compared large-scale gene expression from patients with short or long disease-free survival times, according to the last cycle of chemotherapy, and validated these findings using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and conventional immunohistochemical (IHC) analysis. Samples were selected for microarray evaluation, at the time of diagnosis, using the following criteria: Identical debulking primary surgery, International Federation of Gynaecology and Obstetrics staging, histological subtype and grade. These were divided into 2 groups, regarding the outcome after 2 years of follow-up. Prostaglandin D2 synthase 21 kDa (brain) (PTGDS) was found to be expressed at a significantly higher level in the tumours of patients with a short disease-free survival time, and this was validated by RT-qPCR in all samples. Furthermore, the study evaluated PGD2, the protein product of the PTGDS gene, in a large cohort of 114 HGSOC patients using the Ventana Benchmark automated platform, and IHC positivity was correlated with clinicopathological data and outcome. The global gene expression analysis identified 1,149 genes that were differentially expressed in microarray data, according to the patient outcome. Further analysis RT-qPCR validated PTGDS gene expression in the same samples (r=0.945; P<0.001). IHC analysis showed an inverse profile, with positivity for PGD2 strongly associated with an increase in disease-free survival (P=0.009), the absence of relapse (P=0.039) and sensitivity to platinum-based therapy (P=0.016). Multiple Cox regression showed that IHC evaluation of PGD2 was also a prognostic marker associated with relapse (hazard ratio, 0.37; P=0.002). Overall, the results showed that IHC evaluation of PGD2 is an independent marker of good prognosis in HGSOC. This finding contributes to our understanding of the mechanism of tumour regulation and to investigations into biomarkers that predict response to chemotherapy.
Palavras-chave
high-grade serous ovarian carcinoma, microarray, gene expression, reverse transcription-quantitative polymerase chain reaction, immunohistochemistry, prognosis
URI
https://observatorio.fm.usp.br/handle/OPI/31832
Referências
  1. ABDELHALIM MS, 1977, PROSTAGLANDINS, V14, P633, DOI 10.1016/0090-6980(77)90190-3
  2. Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696
  3. ALAGOZ T, 1994, GYNECOL ONCOL, V53, P93, DOI 10.1006/gyno.1994.1093
  4. Alvarenga AW, 2013, J HISTOCHEM CYTOCHEM, V61, P272, DOI 10.1369/0022155413477661
  5. Armstrong DK, 2002, ONCOLOGIST, V7, P20, DOI 10.1634/theoncologist.7-suppl_5-20
  6. Bachvarov D, 2006, INT J ONCOL, V29, P919
  7. Colombo PE, 2014, CRIT REV ONCOL HEMAT, V89, P207, DOI 10.1016/j.critrevonc.2013.08.017
  8. Cooke SL, 2011, LANCET ONCOL, V12, P1169, DOI 10.1016/S1470-2045(11)70123-1
  9. de Jong E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025192
  10. du Bois A, 2009, CANCER, V115, P1234, DOI 10.1002/cncr.24149
  11. Farhat A, 2011, J OVARIAN RES, V4, DOI 10.1186/1757-2215-4-3
  12. Goff BA, 2013, J GYNECOL ONCOL, V24, P83, DOI 10.3802/jgo.2013.24.1.83
  13. Goossens N, 2015, TRANSL CANCER RES, V4, P256, DOI 10.3978/j.issn.2218-676X.2015.06.04
  14. Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014
  15. Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
  16. Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
  17. ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
  18. KIKUCHI Y, 1986, CANCER RES, V46, P3364
  19. Kim J, 2005, CANCER RES, V65, P6189, DOI 10.1158/0008-5472.CAN-04-4439
  20. Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036
  21. Kurman RJ, 2014, WHO CLASSIFICATION T, V6
  22. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  23. Malpica A, 2004, AM J SURG PATHOL, V28, P496, DOI 10.1097/00000478-200404000-00009
  24. McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101
  25. National institute for health and clinical excellence, 2005, GUID US PACL TREATM
  26. Neijt JP, 2000, J CLIN ONCOL, V18, P3084, DOI 10.1200/JCO.2000.18.17.3084
  27. Payne CA, 2008, MOL CANCER THER, V7, P3420, DOI 10.1158/1535-7163.MCT-08-0629
  28. Petrillo M, 2016, GYNECOL ONCOL, V142, P176, DOI 10.1016/j.ygyno.2016.03.037
  29. Pils D, 2012, CANCER SCI, V103, P1334, DOI 10.1111/j.1349-7006.2012.02306.x
  30. Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
  31. Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520
  32. Rustin GJS, 2004, J NATL CANCER I, V96, P487, DOI 10.1093/jnci/djh081
  33. Rustin GJS, 2011, INT J GYNECOL CANCER, V21, P419, DOI 10.1097/IGC.0b013e3182070f17
  34. Saso L, 1998, BIOCHEM MOL BIOL INT, V46, P643
  35. Shyu RY, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-30
  36. Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
  37. SMITH WL, 1992, AM J PHYSIOL, V263, pF181
  38. Su B, 2001, CLIN CHEM LAB MED, V39, P1198, DOI 10.1515/CCLM.2001.190
  39. Taylor PT, 2005, JNCI-J NATL CANCER I, V97, P151, DOI 10.1093/jnci/dji027
  40. Tippin BL, 2014, CANCER MED-US, V3, P1041, DOI 10.1002/cam4.251
  41. Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185
  42. Wallstrom G, 2013, CANCER EPIDEM BIOMAR, V22, P747, DOI 10.1158/1055-9965.EPI-12-1236
  43. Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001
  44. Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100
  45. Wang MT, 2007, CANCER METAST REV, V26, P525, DOI 10.1007/s10555-007-9096-5
  46. Wang ZGC, 2012, CLIN CANCER RES, V18, P5806, DOI 10.1158/1078-0432.CCR-12-0857
  47. Xie C, 2011, NUCLEIC ACIDS RES, V39, pW316, DOI 10.1093/nar/gkr483
  48. Yoshida T, 1998, SURG TODAY, V28, P740, DOI 10.1007/BF02484622
  49. Yu ZW, 2010, ORAL ONCOL, V46, P317, DOI 10.1016/j.oraloncology.2010.02.002

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/58
Artigos e Materiais de Revistas Científicas - ODS/03